CSF total tau, Aβ42 and phosphorylated tau protein as biomarkers for Alzheimer’s disease

Molecular Neurobiology

Volumn 24, Issue 1-3, 2001, Pages 87-97

  Blennow, Kaj ^a,b   Vanmechelen, Eugeen ^c   Hampel, Harald ^d  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Medical Research Council (MRC)   (Sweden)

^c INNOGENETICS   (Belgium)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Alzheimer's disease (AD); Biochemical markers; Cerebrospinal fluid (CSF); Diagnosis; Phosphorylated tau; Tau; amyloid (A )

Indexed keywords

AMINO ACID; AMYLOID BETA PROTEIN; TAU PROTEIN;

AGING; ALZHEIMER DISEASE; AMNESIA; ARTICLE; CEREBROSPINAL FLUID; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE MARKER; EARLY DIAGNOSIS; GENETIC SCREENING; HUMAN; PHOSPHORYLATION;

EID: 0035691112     PISSN: 08937648     EISSN: None     Source Type: Journal    
DOI: 10.1385/MN:24:1-3:087     Document Type: Article

References (73)

1. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer's disease
2. The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease: A clinicopathologic study of 57 cases
3. Diagnostic accuracy of Alzheimer's disease: A clinicopathological study
4. Clinical-neuropathological correlations in Alzheimer's disease and related dementias
5. Consensus report of the Working Group on "Molecular and Biochemical Markers of Alzheimer's Disease"
6. Tau protein and the neurofibrillary pathology of Alzheimer's disease
7. Detection of τ proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay
8. Tau protein in cerebrospinal fluid: A biochemical diagnostic marker for axonal degeneration in Alzheimer's disease?
9. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease
10. Improved discrimination of AD patients using beta-amyloid (1-42) and tau levels in CSF
11. Cernrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: A community-based follow-up study
12. Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: Multicenter study in Japan
13. A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: Relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele
14. No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia
15. Tau protein in cerebrospinal fluid: A new diagnostic and prognostic marker in Alzheimer disease?
16. Apolipoprotein E genotyping and cerebrospinal fluid tau protein: Implications for the clinical diagnosis of Alzheimer's disease
17. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease
18. Tau and apo E in CSF: Potential aid for discriminating Alzheimer's disease from other dementias
19. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology
20. Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies
21. Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease
22. 1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging
23. Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies
24. Tau protein is a potential biological marker for normal pressure hydrocephalus
25. Increased CSF tau protein in corticobasal degeneration
26. Cerebrospinal fluid tau protein levels in demented and nondemented alcoholics
27. A comparison of tau protein in cerebrospinal fluid between corticobasal degeneration and progressive supranuclear palsy
28. Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischaemic stroke
29. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease
30. Decreased levels of amyloid β 1-42 in cerebrospinal fluid of Creutzfeldt-Jakob disease patients
31. Update on the dementia spectrum of depression
32. Sensitivity, specificity and stability of CSF t-tau in AD in a community-based patient sample
33. Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer's disease compared with controls
34. Transient increase in CSF total tau but not phospho-tau after acute stroke
35. Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231
36. Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression
37. (1-42) in Alzheimer's disease: Differences between early-and late-onset Alzheimer disease and stability during the course of disease
38. Evaluation of CSF t-tau and CSF-Aβ42 as diagnostic markers for Alzheimer's disease in clinical practice
39. Decreased beta-amyloid 1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease
40. Low cerebrosinal fluid β-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment
41. "Mini-Mental State" a practical method for grading the cognitive state of patients for the clinician
42. Mild cognitive impairment: Clinical characterization and outcome
43. Elevated cerebrospinal fluid tau protein level as a predictor of dementia in memory-impaired patients
44. CSF phosphorylated tau protein and mild cognitive impairment: A prospective study
45. Low frequency of post-lumbar puncture headache in demented patients
46. Diagnostic accuracy of Alzheimer's disease: A neuropathological study
47. Some quantitative cerebral findings in normal and emented old people
48. A4 amyloid protein deposition and the diagnosis of Alzheimer's disease
49. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease
50. Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF
51. Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease
52. Increased cerebrospinal fluid tau in patients with Alzheimer's disease
53. Cerebrospinal protein tau is elevated in early Alzheimer's disease
54. Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer's disease
55. Longitudinal study of cerebrospinaI fluid levels of tau, A beta 1-40, and A beta 1-42(43) in Alzheimer's disease: A study in Japan
56. Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer disease
57. CSF tau is related to apolipoprotein E genotype in early Alzheimer's disease
58. (1-42) in CSF
59. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease
60. Both total and hyperphosphorylated tau are increased in Alzeimer's disease
61. Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease
62. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease
63. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype
64. Tau in cerebrospinal fluids: Establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau
65. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients
66. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: A sandwich ELISA with a synthetic phosphopeptide for standardization
67. Cerebrospinal beta-amyloid ((1-42)) in early Alzheimer's disease: Association with apolipoprotein E genotype and cognitive decline
68. Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease
69. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay
70. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease
71. CSF t-tau and CSFAβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment